Safety and anti-tumor activity of Pasireotide in patients with BRAF- and NRAS-wild type, unresectable and or metastatic melanoma: a phase I, open-label, single-arm study

被引：0
|
作者：
Schadendorf, D. [1 ]
Michielin, O. [2 ,3 ]
Nageli, M. [4 ]
Goldinger, S. M. [4 ]
Campigotto, F. [5 ]
Kriemler-Krahn, U. [6 ]
Schmid, H. A. [6 ]
Pedroncelli, A. M. [6 ]
Micaletto, S. [4 ]
Dummer, R. [4 ]
机构：
[1] Univ Hosp Essen, Dept Dermatol, Essen, Germany
[2] Lausanne Univ Hosp CHUV, Multidisciplinary Oncol Ctr, Lausanne, Switzerland
[3] Swiss Inst Bioinformat SIB, Lausanne, Switzerland
[4] Univ Zurich Hosp, Dept Dermatol, Zurich, Switzerland
[5] Novartis Pharmaceut, E Hanover, NJ USA
[6] Novartis Pharmaceut AG, Basel, Switzerland
来源：
MELANOMA RESEARCH | 2016年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P064
引用
收藏
页码：E43 / E44
页数：2
相关论文
共 50 条
  • [1] A phase I, open-label study of pasireotide in patients with BRAF-and NRAS-wild type, unresectable and or metastatic melanoma
    Dummer, R.
    Michielin, O. A.
    Nageli, M.
    Goldinger, S. M.
    Campigotto, F.
    Kriemler-Krahn, U.
    Schmid, H.
    Pedroncelli, A.
    Micaletto, S.
    Schadendorf, D.
    ANNALS OF ONCOLOGY, 2016, 27
  • [2] Phase I, open-label study of pasireotide in patients with BRAF-wild type and NRAS-wild type, unresectable and/or metastatic melanoma
    Dummer, Reinhard
    Michielin, Olivier
    Nageli, Mirjam Chantal
    Goldinger, Simone M.
    Campigotto, Federico
    Kriemler-Krahn, Ulrike
    Schmid, Herbert
    Pedroncelli, Alberto
    Micaletto, Sara
    Schadendorf, Dirk
    ESMO OPEN, 2018, 3 (05)
  • [3] Tucidinostat plus toripalimab in patients with unresectable or metastatic melanoma: An open-label, single-arm phase II study
    Mao, Lili
    Dai, Jie
    Bai, Xue
    Kong, Yan
    Sheng, Xinan
    Chi, Zhihong
    Cui, Chuanliang
    Lian, Bin
    Tang, Bixia
    Yan, Xieqiao
    Wang, Xuan
    Li, Siming
    Zhou, Li
    Wei, Xiaoting
    Li, Juan
    Li, Caili
    Duan, Rong
    Xu, Huayan
    Guo, Jun
    Si, Lu
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [4] Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study
    Mao, Lili
    Fang, Meiyu
    Chen, Yu
    Wei, Xiaoting
    Cao, Jun
    Lin, Jing
    Zhang, Peng
    Chen, Ling
    Cao, Xiao
    Chen, Yujun
    Guo, Jun
    Si, Lu
    CLINICAL CANCER RESEARCH, 2022, 28 (21) : 4642 - 4648
  • [5] Atezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: A multicenter, open-label, single-arm phase 2 study.
    Mao, Lili
    Fang, Meiyu
    Chen, Yu
    Bai, Xue
    Cao, Jun
    Lin, Jing
    Zhang, Peng
    Chen, Ling
    Xu, Jiahui
    Guo, Jun
    Si, Lu
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [6] Safety and Efficacy of Apatinib Monotherapy for Unresectable, Metastatic Esophageal Cancer: A Single-Arm, Open-Label, Phase II Study
    Li Yanwei
    Feng, He
    Ren, Peng
    Yue, Jie
    Zhang, Wencheng
    Tang, Peng
    Shang, Xiaobin
    Pang, Qingsong
    Liu, Dongying
    Chen, Chuangui
    Pan, Zhanyu
    Tao, Yu Zhen
    ONCOLOGIST, 2020, 25 (10): : E1464 - E1472
  • [7] Efficacy and safety of tunlametinib in patients with advanced NRAS-mutant melanoma: A multicenter, open-label, single-arm, phase 2 study.
    Si, Lu
    Zou, Zhengyun
    Zhang, Weizhen
    Fang, Meiyu
    Zhang, Xiaoshi
    Luo, Zhiguo
    Chen, Jing
    Huang, Gang
    Zhang, Peng
    Cheng, Ying
    Liu, Jiwei
    Liu, Jiyan
    Zhang, Junping
    Wu, Di
    Chen, Yu
    Ma, Xiaobiao
    Wei, Xiaoting
    Sun, Peng
    Jia, Zhongwei
    Guo, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [8] Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study
    McArthur, G. A.
    Maio, M.
    Arance, A.
    Nathan, P.
    Blank, C.
    Avril, M. -F.
    Garbe, C.
    Hauschild, A.
    Schadendorf, D.
    Hamid, O.
    Fluck, M.
    Thebeau, M.
    Schachter, J.
    Kefford, R.
    Chamberlain, M.
    Makrutzki, M.
    Robson, S.
    Gonzalez, R.
    Margolin, K.
    ANNALS OF ONCOLOGY, 2017, 28 (03) : 634 - 641
  • [9] Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study
    Zager, Jonathan S.
    Orloff, Marlana
    Ferrucci, Pier Francesco
    Choi, Junsung
    Eschelman, David J.
    Glazer, Evan S.
    Ejaz, Aslam
    Howard, J. Harrison
    Richtig, Erika
    Ochsenreither, Sebastian
    Reddy, Sunil A.
    Lowe, Michael C.
    Beasley, Georgia M.
    Gesierich, Anja
    Bender, Armin
    Gschnell, Martin
    Dummer, Reinhard
    Rivoire, Michel
    Arance, Ana
    Fenwick, Stephen William
    Sacco, Joseph J.
    Haferkamp, Sebastian
    Weishaupt, Carsten
    John, Johnny
    Wheater, Matthew
    Ottensmeier, Christian H.
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (08) : 5340 - 5351
  • [10] A single-arm, open-label, US expanded access study of vemurafenib in patients with metastatic melanoma.
    Schuchter, Lynn Mara
    Flaherty, Lawrence E.
    Hamid, Omid
    Linette, Gerald P.
    Hallmeyer, Sigrun
    Gonzalez, Rene
    Cowey, Charles Lance
    Pavlick, Anna C.
    Kudrik, Fred J.
    Lawson, David H.
    Margolin, Kim Allyson
    Ribas, Antoni
    McDermott, David F.
    Khatcheressian, James L.
    Flaherty, Keith T.
    Day, Bann-Mo
    Linke, Rolf Gerhard
    Hainsworth, John D.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345